Table 2. Baseline characteristics of the study population stratified by the status of subclinical thyroid function.
| Variable | Euthyroidism group (n = 411) | SHyper group (n = 56) | P* | SHypo group (n = 96) | P# |
| Demographics data | |||||
| Age, year | 67.3 ± 11.7 | 65.1 ± 11.2 | 0.207 | 66.8 ± 12.9 | 0.691 |
| Male, % | 247 (60.1) | 33 (58.9) | 0.867 | 49 (51.0) | 0.105 |
| Vascular risk factors, % | |||||
| Hypertension | 283 (68.9) | 48 (85.7) | 0.009 | 59 (61.5) | 0.164 |
| Diabetes mellitus | 105 (25.5) | 12 (21.4) | 0.505 | 34 (35.4) | 0.049 |
| Hyperlipidemia | 50 (12.2) | 5 (9.1) | 0.477 | 17 (17.7) | 0.155 |
| Coronary heart disease | 67 (16.3) | 8 (14.5) | 0.739 | 24 (25.0) | 0.046 |
| Atrial fibrillation | 115 (28.0) | 20 (35.7) | 0.231 | 26 (27.1) | 0.860 |
| Smoking | 157 (39.0) | 19 (36.5) | 0.806 | 31 (32.3) | 0.273 |
| Clinical data | |||||
| Previous antiplatelet, % | 85 (20.7) | 13 (24.5) | 0.524 | 17 (17.7) | 0.506 |
| Previous statin, % | 34 (8.3) | 7 (12.5) | 0.294 | 10 (10.4) | 0.502 |
| Systolic blood pressure, mmHg | 136.8 ± 20.9 | 137.5 ± 24.8 | 0.760 | 136.2 ± 21.3 | 0.892 |
| Diastolic blood pressure, mmHg | 88.1 ± 14.8 | 85.4 ± 14.5 | 0.217 | 86.2 ± 12.8 | 0.252 |
| Body mass index, kg/m2 | 24.1 ± 3.2 | 24.5 ± 3.8 | 0.366 | 24.4 ± 3.2 | 0.451 |
| Onset to blood drawing time, h | 11.0 (6.0, 17.0) | 11.0 (6.0, 16.0) | 0.592 | 10.0 (6.0, 15.0) | 0.277 |
| Baseline NIHSS, score | 8.0 (4.0, 13.0) | 11.0 (4.0, 19.0) | 0.076 | 5.0 (3.0, 11.0) | 0.010 |
| Onset to treatment time, minutes | 144.8 ± 61.4 | 148.7 ± 69.0 | 0.657 | 142.6 ± 65.0 | 0.767 |
| Imaging data | |||||
| ASPECTS at admission | 9.0 (9.0, 10.0) | 9.0 (9.0, 10.0) | 0.616 | 9.0 (9.0, 10.0) | 0.793 |
| ASPECTS at 24 h | 8.0 (6.0, 9.0) | 7.0 (5.0, 9.0) | 0.061 | 8.0 (6.0, 9.0) | 0.384 |
| Vascular occlusion, %† | 178 (46.6) | 30 (56.6) | 0.183 | 47 (51.1) | 0.465 |
| sICH, % | 22 (5.4) | 6 (10.7) | 0.113 | 2 (2.1) | 0.174 |
| Lesion location, % | 0.467 | 0.815 | |||
| Frontal lobe | 98 (23.8) | 19 (33.9) | 19 (19.8) | ||
| Parietal lobe | 40 (9.7) | 4 (7.1) | 7 (7.3) | ||
| Basal ganglia | 118 (28.7) | 16 (28.6) | 31 (32.3) | ||
| Posterior fossa | 76 (18.5) | 10 (17.9) | 19 (19.8) | ||
| Other | 79 (19.2) | 7 (12.5) | 20 (20.8) | ||
| Stroke subtype, % | 0.116 | 0.364 | |||
| Large artery atherosclerosis | 161 (39.2) | 29 (51.8) | 41 (42.7) | ||
| Cardioembolism | 107 (26.0) | 14 (25.0) | 20 (20.8) | ||
| Small vessel occlusion | 88 (21.4) | 11 (19.6) | 26 (27.1) | ||
| Others | 55 (13.4) | 2 (3.6) | 9 (9.4) | ||
| Clinical outcomes, % | |||||
| Early neurological deterioration | 56 (13.6) | 19 (33.9) | 0.001 | 8 (8.3) | 0.160 |
| Unfavorable outcome at 3 months | 205 (49.9) | 40 (71.4) | 0.003 | 41 (42.7) | 0.206 |
| Mortality at 3 months | 33 (8.0) | 16 (28.6) | 0.001 | 4 (4.2) | 0.190 |
| Thyroid function tests | |||||
| TSH, mIU/L | 1.3 (0.9, 1.7) | 0.3 (0.2, 0.4) | 0.001 | 3.4 (2.8, 4.1) | 0.001 |
| Free T3, pmol/L | 4.8 ± 0.9 | 4.9 ± 0.9 | 0.603 | 4.8 ± 0.9 | 0.944 |
| Free T4, pmol/L | 14.6 ± 2.8 | 14.6 ± 2.7 | 0.735 | 14.1 ± 2.7 | 0.154 |
| Laboratory findings | |||||
| TC, mmol/L | 4.4 ± 1.1 | 4.4 ± 1.0 | 0.911 | 4.6 ± 1.2 | 0.278 |
| TG, mmol/L | 1.2 (0.9, 1.8) | 1.1 (0.8, 1.8) | 0.675 | 1.4 (1.1, 2.3) | 0.018 |
| LDL, mmol/L | 2.6 (2.1, 3.3) | 2.8 (2.1, 3.3) | 0.512 | 2.6 (2.1, 3.2) | 0.972 |
| HDL, mmol/L | 1.2 ± 0.3 | 1.2 ± 0.3 | 0.802 | 1.2 ± 0.4 | 0.742 |
| FGB, mmol/L | 6.3 ± 2.2 | 6.4 ± 2.2 | 0.703 | 6.5 ± 2.8 | 0.464 |
| Homocysteine, umol/L | 15.7 ± 9.2 | 16.1 ± 7.4 | 0.795 | 15.2 ± 8.0 | 0.586 |
| Hs-CRP, mg/L | 5.7 (2.3, 12.3) | 8.4 (2.0, 11.6) | 0.388 | 5.0 (2.0, 12.5) | 0.343 |
Abbreviations: ASPECTS: alberta stroke program early CT score; FGB: fasting blood glucose; HDL: high density lipoprotein; Hs-CRP: high-sensitivity C-reactive protein; LDL: low density lipoprotein; NIHSS: national institutes of health stroke scale; SHyper: subclinical hyperthyroidism; SHypo: subclinical hypothyroidism; sICH: symptomatic intracranial hemorrhage; TC: total cholesterol; TG: triglyceride; TSH: thyroid stimulating hormone.
*Univariate analysis between SHyper group and euthyroidism group;
#Univariate analysis between SHypo group and euthyroidism group;
†Data available for 525 patients.